sustain 6 trial semaglutide BJD Post hoc analysis of SUSTAIN

MASLD proposes to define metabolic dysfunction as its basis, resulting in a greater disease impact and less heterogeneity, where overweight/obese patients and the presence of type 2 diabetes mellitus (T2DM) will be the most important criteria

Reduced, bioactive form

This approach harnesses complementary hormone pathways while remaining within established pharmacological frameworks and supported by emerging clinical data on combination GLP-1/GIP therapy

Microchim Acta 181:14071413 Wu P, Hu F, Wang R, Gao L, Huang T, Xin Y, He H (2018) Colorimetric chiral recognition of D/L-phenylalanine based on triangular silver nanoplates